



# biotricity CORPORATION PROFILE

February 14, 2020

OTC.QB:BTCY

INNOVATIVE • MEDICAL GRADE BIOMETRIC REMOTE MONITORING SOLUTIONS

## KEY STATS

February 14, 2020

**Stock Price** \$2.03 +0.1150 (+6.01%)

**52 Week Low-High** \$0.26 - \$2.21

**Market Cap** \$73.279M



## ABOUT BIOTRICITY INC.

Biotricity's mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. A medical technology company, Biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement.



The company has developed a proprietary platform technology (encompassing cellular IoT, FDA and HIPAA compliant device OS, Cloud, Big Data and AI) that has applications for a wide range of adjacent connected healthcare markets.



Our first solution, Bioflux®, addresses the growing and underserved market of Mobile Cardiac Telemetry (MCT) with a technologically superior and more financially attractive choice for medical practitioners. The Bioflux® system is a complete solution for remote cardiac monitoring, merging seamlessly with physicians' existing platforms and workflows to enable better detection, diagnosis, and monitoring. The Bioflux® solution is insurance reimbursable across Medicare and Private insurance.



Currently, the Company has expanded across 12 states and is experiencing high double digit to triple digit growth quarter over quarter as a result of its novel technology and residual income business model. With a technology-as-a-service business model, the Company is in a unique position to drive growth while ensuring long term residual income.

## RESEARCH & DEVELOPMENT PARTNERSHIPS

Biotricity has established several partnerships. Working with Rare Genomic's RareWear initiative is part of the company's focus to expand its current deep data sets to drive additional insights for predictive monitoring.

Biotricity is also partnering with the Biomedical Engineering Department at the University of Calgary and the U of C Cumming School of Medicine to explore and develop effective representations of both fetal/maternal heart rate variability (HRV) and electro-hysterography (labor contraction monitoring) in pregnancy. The company will facilitate all parties in their investigation to determine what role artificial intelligence can play in assisting with clinical interpretation. Combining Biotricity's high-fidelity electrically based monitoring with actual clinical data and BME's proven engineering expertise, the U of C/Biotricity program is expected to produce systems to facilitate mobile monitoring for both mothers and babies prior to and during delivery.

Today, Biotricity is actively monitoring patients and anomalies. In the future, we will move into predictive monitoring with telemedicine, and our solutions will be able to detect issues before they occur. It is through partnerships like the RareWear initiative and the fetal/maternal HRV research and development that Biotricity will drive deeper insights into clinical issues and hone its platform, moving towards predictive monitoring.

## RECENT NEWS HIGHLIGHTS

**February 18, 2020:** Biotricity posts calendar Q4 results that show continued growth

**February 13, 2020:** Biotricity files a 510(k) application for its advanced ECG analysis software


**January 22, 2020:** Biotricity prepares its filing for a 510(k) application for its advanced ECG analysis software

### MARKET GROWTH

The total connected health market is growing at a 27.6% CAGR, reaching \$188 billion by 2024<sup>1</sup>

#### CONNECTED HEALTH MARKET<sup>1</sup>

WILL GROW 33% CAGR BY 2020



#### COMPETITIVE ADVANTAGES OF BIOTRICITY'S MCT SOLUTION:

1. Equivalent diagnostics to current MCT solutions
2. Recurring reimbursements to doctors, hospitals and IDTFs
3. Revenue model fits within established insurance billing codes
4. Built-in cellular connectivity enables emergency response
5. Motion tracking enables detection of exercise, activity, and disorientation
6. Technology is easily adaptable for opportunities adjacent to the MCT market

<sup>1</sup><https://www.businesswire.com/news/home/20200103005328/en/Global-IoT-Healthcare-Market-Study-2020-2024-Featuring>

The information contained herein has been prepared to assist interested parties in making their own evaluation of Biotricity and does not purport to contain all of the information that any such party may require. Therefore, parties should conduct their own investigations and analysis. This document includes certain statements, estimates, and projections with respect to the anticipated future performance of the Company. These reflect various assumptions made by the management of Biotricity concerning anticipated results, which involve significant elements of subjective judgement and analysis and may or may not prove to be correct. No representation or warranty is made to the accuracy of such statements, estimates or projections.



biotricity

Biotricity Investor Relations

1.800.951.3348

investors@biotricity.com